3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
52
Terminated
17
Recruiting
12
Unknown
11
Active not recruiting
9
Withdrawn
3
Not yet recruiting
2
No longer available
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
2
Waldenstrom Macroglobulinemia
1
Vascular Malformations
1
Unresectable Locally Advanced or Metastatic Solid Tumors
1
Triple Negative Breast Neoplasms
1
Skin Neoplasms
1
Phase IB
1
Nevus
1
Neoplasms, Plasma Cell
1
Lymphoma
1
Lymphangioma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hemangioma
1
Hemangioendothelioma
1
Hamartoma Syndrome, Multiple
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Hepatocellular
1
Bone Neoplasms
1
Autistic Disorder
1
Arteriovenous Malformations
1
Interventions
Trastuzumab
16
pertuzumab
14
Capecitabine
14
Docetaxel
12
pyrotinib
11
Cyclophosphamide
11
Standard of Care
10
Paclitaxel
10
Letrozole
10
trastuzumab deruxtecan
9
Radiotherapy
9
Carboplatin
9
Fulvestrant
8
Drug Therapy
8
sacituzumab govitecan
7
dalpiciclib
7
exemestane
6
eribulin
6
Tamoxifen
6
Epirubicin
6
Anastrozole
6
pembrolizumab
5
palbociclib
5
abemaciclib
5
Surveys and Questionnaires
5
Neoadjuvant Therapy
5
Aromatase Inhibitors
5
camrelizumab
4
Sentinel Lymph Node Biopsy
4
Doxorubicin
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Breast Neoplasms
×
Everolimus
×
Clear all
NCT07407517
2026-02-12
POLARIS
Fudan University
Phase 3
Not yet recruiting
904 enrolled
NCT06561022
2024-08-19
abemaSNF1/3
Fudan University
Phase 2
Not yet recruiting
260 enrolled